SCYNEXIS, Inc. (SCYX) Announces Changes To Board Of Directors

RESEARCH TRIANGLE PARK, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the following changes to its Board of Directors:

Guy Macdonald has been appointed Chairman of the Board of Directors, effective as of June 4, 2015. Mr. Macdonald has been an independent director at SCYNEXIS since November 2014. Mr. Macdonald will continue to serve on the company's compensation committee.
Pamela J. Kirby, Ph.D., did not stand for reelection and has retired from SCYNEXIS' Board, effective June 4, 2015. Dr. Kirby joined the Board in December 2004, and has served as Chairman of the Board since January 2006.
Laurent Arthaud and Jean-Yves Nothias, Ph.D., also did not stand for reelection and have retired from SCYNEXIS' Board, effective June 4, 2015. Mr. Arthaud and Dr. Nothias joined SCYNEXIS' Board in 2007 and 2000, respectively, at the time of venture capital investments made in the company by their affiliated funds, prior to SCYNEXIS' initial public offering.
SCYNEXIS' Board of Directors now comprises seven members, as follows: Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer; Yves Ribeill, Ph.D., SCYNEXIS' President; and five independent directors, Mr. Macdonald, Steven C. Gilman, Ph.D., Ann F. Hanham, Ph.D., Patrick J. Langlois, Ph.D., and Edward E. Penhoet, Ph.D.

"Guy Macdonald has been a strong contributor to the Board since his appointment last year, bringing great insights and expertise arising from his successful experiences with drug development and commercialization, particularly within the field of anti-infectives, and I look forward to Guy's continued contributions from his new leadership position on our Board," said Dr. Taglietti. "On behalf of the Board of Directors and the company, I would like to thank Pam, Laurent and Jean-Yves for their collective strategic guidance and oversight as we've grown from a privately-held services-based organization to a clinically-focused public company."

Mr. Macdonald is President, Chief Executive Officer and board member of Tetraphase Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel antibiotics for multidrug-resistant infections. Prior to joining Tetraphase in 2008, he was the Executive Vice President of Operations at Idenix Pharmaceuticals, Inc. and held various positions at Merck & Co., most recently as Vice President for Anti-infective and Hospital Products.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit

CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 [email protected] Investor Relations Jillian Connell The Trout Group LLC Tel: 646.378.2956 [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.